Perrigo’s Pivot To Building Brand Market Share Boosted With Opill OTC Oral Contraceptive Approval

 
• By Malcolm Spicer

Year after acquiring HRA, Perrigo makes preparations to launch arguably the most anticipated OTC switch in US pharma history, Opill with 0.075-mg norgestel. Analysts estimate $100m annual market for OTC birth control.

• Source: Shutterstock/FDA

More from Strategy

More from Business